Elanco Animal Health Incorporated (ELAN)

Market Cap	4.19B
Revenue (ttm)	4.44B
Net Income (ttm)	338.00M
Shares Out	496.46M
EPS (ttm)	0.68
PE Ratio	12.41
Forward PE	10.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,406,237
Open	8.09
Previous Close	8.10
Day's Range	8.03 - 8.46
52-Week Range	8.03 - 18.80
Beta	1.44
Analysts	Buy
Price Target	14.67 (+73.82%)
Earnings Date	May 7, 2025

About ELAN

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 20, 2018
• Employees: 9,450
• Stock Exchange: NYSE
• Ticker Symbol: ELAN
• Website: https://www.elanco.com

Analyst Forecast

According to 6 analysts, the average rating for ELAN stock is "Buy." The 12-month stock price forecast is $14.67, which is an increase of 73.82% from the latest price.

Price Target

$14.67

(73.82% upside)

Analyst Consensus: Buy